Literature DB >> 26228485

Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation.

Diamantis G Konstantinidis1, Katie M Giger1, Mary Risinger2, Suvarnamala Pushkaran1, Ping Zhou1, Phillip Dexheimer3, Satwica Yerneni3, Paul Andreassen1, Ursula Klingmüller4, James Palis5, Yi Zheng1, Theodosia A Kalfa1.   

Abstract

RhoA GTPase has been shown in vitro in cell lines and in vivo in nonmammalian organisms to regulate cell division, particularly during cytokinesis and abscission, when 2 daughter cells partition through coordinated actomyosin and microtubule machineries. To investigate the role of this GTPase in the rapidly proliferating mammalian erythroid lineage, we developed a mouse model with erythroid-specific deletion of RhoA. This model was proved embryonic lethal as a result of severe anemia by embryonic day 16.5 (E16.5). The primitive red blood cells were enlarged, poikilocytic, and frequently multinucleated, but were able to sustain life despite experiencing cytokinesis failure. In contrast, definitive erythropoiesis failed and the mice died by E16.5, with profound reduction of maturing erythroblast populations within the fetal liver. RhoA was required to activate myosin-regulatory light chain and localized at the site of the midbody formation in dividing wild-type erythroblasts. Cytokinesis failure caused by RhoA deficiency resulted in p53 activation and p21-transcriptional upregulation with associated cell-cycle arrest, increased DNA damage, and cell death. Our findings demonstrate the role of RhoA as a critical regulator for efficient erythroblast proliferation and the p53 pathway as a powerful quality control mechanism in erythropoiesis.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26228485      PMCID: PMC4573870          DOI: 10.1182/blood-2014-12-616169

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  62 in total

Review 1.  Cre recombinase: the universal reagent for genome tailoring.

Authors:  A Nagy
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  The Rho family GTPase Rif induces filopodia through mDia2.

Authors:  Stéphanie Pellegrin; Harry Mellor
Journal:  Curr Biol       Date:  2005-01-26       Impact factor: 10.834

3.  Cytokinesis failure triggers hippo tumor suppressor pathway activation.

Authors:  Neil J Ganem; Hauke Cornils; Shang-Yi Chiu; Kevin P O'Rourke; Jonathan Arnaud; Dean Yimlamai; Manuel Théry; Fernando D Camargo; David Pellman
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

4.  Enhancement of mDia2 activity by Rho-kinase-dependent phosphorylation of the diaphanous autoregulatory domain.

Authors:  Dean P Staus; Joan M Taylor; Christopher P Mack
Journal:  Biochem J       Date:  2011-10-01       Impact factor: 3.857

5.  Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Authors:  Shilpee Dutt; Anupama Narla; Katherine Lin; Ann Mullally; Nirmalee Abayasekara; Christine Megerdichian; Frederick H Wilson; Treeve Currie; Arati Khanna-Gupta; Nancy Berliner; Jeffery L Kutok; Benjamin L Ebert
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

6.  Rho and anillin-dependent control of mDia2 localization and function in cytokinesis.

Authors:  Sadanori Watanabe; Katsuya Okawa; Takashi Miki; Satoko Sakamoto; Tomoko Morinaga; Kohei Segawa; Takatoshi Arakawa; Makoto Kinoshita; Toshimasa Ishizaki; Shuh Narumiya
Journal:  Mol Biol Cell       Date:  2010-07-21       Impact factor: 4.138

7.  Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen.

Authors:  Theodosia A Kalfa; Suvarnamala Pushkaran; Xiaoling Zhang; James F Johnson; Dao Pan; Deidre Daria; Hartmut Geiger; Jose A Cancelas; David A Williams; Yi Zheng
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

8.  Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family.

Authors:  Nadia Danilova; Kathleen M Sakamoto; Shuo Lin
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

9.  Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23.

Authors:  Maria Liljeholm; Andrew F Irvine; Ann-Louise Vikberg; Anna Norberg; Stacy Month; Herbert Sandström; Anders Wahlin; Masanori Mishima; Irina Golovleva
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113

Review 10.  Primitive and definitive erythropoiesis in mammals.

Authors:  James Palis
Journal:  Front Physiol       Date:  2014-01-28       Impact factor: 4.566

View more
  11 in total

1.  Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.

Authors:  Alessandro Matte; Enrica Federti; Michael Winter; Annette Koerner; Anja Harmeier; Norman Mazer; Tomas Tomka; Maria Luisa Di Paolo; Luigia De Falco; Immacolata Andolfo; Elisabetta Beneduce; Achille Iolascon; Alejandra Macias-Garcia; Jane-Jane Chen; Anne Janin; Christhophe Lebouef; Franco Turrini; Carlo Brugnara; Lucia De Franceschi
Journal:  JCI Insight       Date:  2019-11-14

Review 2.  Mouse Models of Erythropoiesis and Associated Diseases.

Authors:  Matthew P Parker; Kenneth R Peterson
Journal:  Methods Mol Biol       Date:  2018

3.  Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis.

Authors:  Elisabetta Beneduce; Alessandro Matte; Luigia De Falco; Serge Mbiandjeu; Deborah Chiabrando; Emanuela Tolosano; Enrica Federti; Sara Petrillo; Narla Mohandas; Angela Siciliano; Wilson Babu; Vijay Menon; Saghi Ghaffari; Achille Iolascon; Lucia De Franceschi
Journal:  Am J Hematol       Date:  2018-10-25       Impact factor: 10.047

4.  Requirement for antiapoptotic MCL-1 during early erythropoiesis.

Authors:  Meghan E Turnis; Ewa Kaminska; Kaitlyn H Smith; Brittany J Kartchner; Peter Vogel; Jonathan D Laxton; Richard A Ashmun; Paul A Ney; Joseph T Opferman
Journal:  Blood       Date:  2021-04-08       Impact factor: 25.476

5.  ARHGEF12 regulates erythropoiesis and is involved in erythroid regeneration after chemotherapy in acute lymphoblastic leukemia patients.

Authors:  Yangyang Xie; Li Gao; Chunhui Xu; Liming Chu; Lei Gao; Ruichi Wu; Yu Liu; Ting Liu; Xiao-Jian Sun; Ruibao Ren; Jingyan Tang; Yi Zheng; Yong Zhou; Shuhong Shen
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

6.  Cholesterol-binding protein TSPO2 coordinates maturation and proliferation of terminally differentiating erythroblasts.

Authors:  Benjaporn Kiatpakdee; Kota Sato; Yayoi Otsuka; Nobuto Arashiki; Yuqi Chen; Takuya Tsumita; Wataru Otsu; Akito Yamamoto; Reo Kawata; Jumpei Yamazaki; Yoshikazu Sugimoto; Kensuke Takada; Narla Mohandas; Mutsumi Inaba
Journal:  J Biol Chem       Date:  2020-05-01       Impact factor: 5.157

Review 7.  Rho GTPases Signaling in Zebrafish Development and Disease.

Authors:  Marie-José Boueid; Aya Mikdache; Emilie Lesport; Cindy Degerny; Marcel Tawk
Journal:  Cells       Date:  2020-12-08       Impact factor: 6.600

8.  Up-regulation of ST18 in pemphigus vulgaris drives a self-amplifying p53-dependent pathomechanism resulting in decreased desmoglein 3 expression.

Authors:  Sari Assaf; Dan Vodo; Kiril Malovitski; Janan Mohamad; Shir Bergson; Yarden Feller; Liron Malki; Ofer Sarig; Eli Sprecher
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

9.  Unraveling Macrophage Heterogeneity in Erythroblastic Islands.

Authors:  Katie Giger Seu; Julien Papoin; Rose Fessler; Jimmy Hom; Gang Huang; Narla Mohandas; Lionel Blanc; Theodosia A Kalfa
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561

10.  Role of Plasma Gelsolin Protein in the Final Stage of Erythropoiesis and in Correction of Erythroid Dysplasia In Vitro.

Authors:  So Yeon Han; Eun Mi Lee; Suyeon Kim; Amy M Kwon; Eun Jung Baek
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.